A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older

phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older. 300 subjects will be enrolled and divided into 5 age groups: 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group and 3-8 years old group. In each group, there are two regimen cohort: low-dose at 0,30, 60 schedule and high-dose at 0,30,60 schedule. The subjects in regimen cohort will be randomized to receive vaccines or placebos at a ratio of 2:1.

Phase II clinical study will explore dose and immunization procedures in 5 age groups, including 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group, and 3-8 years old group, with a total of 3280 subjects.

Study Overview

• Status: Active, not recruiting
• Conditions: COVID-19
• Intervention / Treatment: Biological: placebo; Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

• Study Type: Interventional
• Enrollment (Actual): 3100
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • He Nan
    • Shang Qiu, He Nan, China
      • Ning ling Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age range: healthy people aged 3 years and and older who can provide legal identification;
• The subject and/or his legal guardian and/or his entrusted person can understand the study procedures and informed consent, voluntarily sign informed consent form, and be able to comply with the requirements of the clinical study protocol;
• Inquired about medical history and physical examination, the investigator judged that the health condition is good;
• No history of SARS-CoV-2 vaccination before enrollment;
• Females of childbearing age (menarche to menopause) are not pregnant at the time of enrollment (negative urine pregnancy test), not breastfeeding, and have no birth plan within 12 months after enrollment; effective contraception will be taken within 2 weeks before enrollment;
• During the entire study follow-up period, be able and willing to complete the entire prescribed study plan.

Exclusion Criteria:

First Dose Exclusion Criteria：

• Confirmed cases of SARS-CoV-2 infection, suspected cases, asymptomatic infections, or close contacts with the above population (check "China Disease Prevention and Control Information System");
• Axillary body temperature is not less than 37.3℃ (older than 14 years) before vaccination, and axillary body temperature is not less than 37.5℃ (14 years or younger) before vaccination;
• Positive in SARS-CoV-2 IgG and IgM antibody screening;
• Have a history of SARS virus infection (self-report, on-site inquiry);
• Fever (axillary temperature is not less than 37.3℃), dry cough, fatigue, nasal, congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, or dyspnea within 14 days before vaccination;
• Before vaccination, the results of blood biochemistry, blood routine, urine routine, and coagulation function related indexes are abnormal, which exceed the reference value range, and have clinical significance abnormalities (only refers to phase I);
• Previous severe allergic reaction to vaccination (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain);
• Allergic to any component of the study vaccine (such as aluminum, histidine, etc.);
• Have a history of convulsions, epilepsy, encephalopathy, long-term alcoholism and drug abuse, thyroidectomy, infectious diseases, mental illness or family history;
• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
• Known or suspected diseases include: severe respiratory disease, severe liver and kidney disease, severe cardiovascular disease, drug-uncontrollable hypertension (systolic blood pressure is not less than 140mmHg, diastolic blood pressure is not less than 90mmHg), high blood glucose, diabetic complications , Malignant tumors, various acute diseases or acute attacks of chronic diseases;
• Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
• Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy);
• Asthenia or splenectomy, functional asthenia caused by any situation;
• Are receiving anti-TB (tuberculosis) treatment;
• Have received immune enhancement or inhibitor therapy within 3 months (continuous oral or instillation for more than 14 days);
• Have received a live attenuated vaccine within 28 days before vaccination, or received other vaccines within 14 days before vaccination;
• Have received blood products within 3 months before vaccination;
• Have received other study drugs within 6 months before vaccination;
• Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
• Other conditions considered by the investigator to be inappropriate for participation in the study.

Exclusion criteria for the second and third doses of vaccination

• Positive urine pregnancy test;
• Have a high fever (axillary temperature is not less than 39.0℃) for three days and severe allergic reaction after the previous dose of vaccination;
• Severe adverse reactions that are causally related to the previous dose of vaccination;
• For those newly discovered or newly identified after the previous dose of vaccine that does not meet the first dose selection criteria or meets the first dose exclusion criteria, the investigator will determine whether to continue participating in the study;
• Other exclusion reasons considered by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

15

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Phase 1 low-dose group	Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 1 high-dose group	Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
PLACEBO_COMPARATOR: Phase 1 placebo group	Biological: placebo; Intramuscular injection of placebo in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 low-dose group A	Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 low-dose group B	Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 low-dose group C	Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 low-dose group D	Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 high-dose group A	Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 high-dose group B	Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 high-dose group C	Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
EXPERIMENTAL: Phase 2 high-dose group D	Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell); Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
PLACEBO_COMPARATOR: Phase 2 placebo group A	Biological: placebo; Intramuscular injection of placebo in the deltoid muscle of the upper arm
PLACEBO_COMPARATOR: Phase 2 placebo group B	Biological: placebo; Intramuscular injection of placebo in the deltoid muscle of the upper arm
PLACEBO_COMPARATOR: Phase 2 placebo group C	Biological: placebo; Intramuscular injection of placebo in the deltoid muscle of the upper arm
PLACEBO_COMPARATOR: Phase 2 placebo group D	Biological: placebo; Intramuscular injection of placebo in the deltoid muscle of the upper arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination	Phase 1	through 30 minutes after each dose
the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine on the 4th day after each dose of vaccination	Phase 1	4th day each dose
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination	Phase 1	through 7 days after each dose
the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination	Phase 1	through 30 days after each dose
the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination	Phase 1	through 30 days after each dose
the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination	Phase 1	up to 12 months after the full course of vaccination
the incidence of AESI from the first dose of vaccination to 12 months after the full course of vaccination	Phase 1	up to 12 months after the full course of vaccination
Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody(wild Strains) on the 15th day after the full course of vaccination	Phase 1	15th day after the full course of vaccination
the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination	Phase 2	through 30 minutes after each dose
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination	Phase 2	through 7 days after each dose
the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination	Phase 2	through 30 days after each dose
the incidence and severity of non-collective adverse reactions/events within 40 days after each dose of vaccination	Phase 2	through 40 days after each dose
the incidence and severity of non-collective adverse reactions/events within 60 days after each dose of vaccination	Phase 2	through 60 days after each dose
the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination	Phase 2	through 30 days after each dose
the incidence and severity of adverse events leading to withdrawal within 40 days after each dose of vaccination	Phase 2	through 40 days after each dose
the incidence and severity of adverse events leading to withdrawal within 60 days after each dose of vaccination	Phase 2	through 60 days after each dose
the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination	Phase 2	up to 12 months after the full course of vaccination
the incidence of AESI from the the first dose of vaccination to 12 months after the full course of vaccination	Phase 2	up to 12 months after the full course of vaccination
Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody (wild Strains) on the 15th day after the full course of vaccination	Phase 2	15th day after the full course of vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Live SARS-CoV-2 neutralization assay) On the 30th day after the full course of vaccination, the neutralizing antibody level (wild Strains)	Phase 1	30th day after the full course of vaccination
Seroconversion and Geometric Mean Titer (GMT) of SARS-CoV-2-Specific Binding Antibody (IgG) Before each dose, the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after full course of vaccination	Phase 1	before each dose , the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old group before each dose and on the 15th and 30th day after the full course of vaccination	Phase 1	before each dose，the 15th, 30th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-COV-2 specific neutralizing antibody (live SARS-CoV-2 neutralization assay)) On the 30th day after the full course of vaccination	Phase 2	30th day after the full course of vaccination
Two-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Two-dose group: Seroconversion before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Two-dose group: Binding Antibody (IgG) before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group:Seroconversion before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group:Binding Antibody (IgG) before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination	Phase 2	before each dose，the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old 0,30,60 group before each dose , the 15th and 30th day after the full course of vaccination	Phase 2	before each dose, 15th, 30th day after the full course of vaccination

Collaborators and Investigators

• Sponsor: National Vaccine and Serum Institute, China
• Collaborators: Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 25, 2021
• Primary Completion (ANTICIPATED): March 1, 2023
• Study Completion (ANTICIPATED): March 1, 2023

Study Registration Dates

• First Submitted: April 24, 2021
• First Submitted That Met QC Criteria: April 29, 2021
• First Posted (ACTUAL): May 3, 2021

Study Record Updates

• Last Update Posted (ACTUAL): February 2, 2023
• Last Update Submitted That Met QC Criteria: January 31, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: COVID-19
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: 2021-YM-006-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No